Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
345
resultados
Última actualización
16/10/2026 [07:35:00]
Resultados 250 a 275 de 345
Resumen de: US20260259202A1
0000 Proper functioning of the human body relies on the organization of cells in 3D space. A cell's function and fate are determined by its biomolecule composition and 3D environment. The spatial identification of proteins, RNAs, DNAs, and other biomolecules in a tissue thus provides a powerful map to decipher how cells build tissues and become diseased. Thus, described herein are methods and compositions for assessing biomolecule identity (the present invention features methods and compositions for assessing biomolecule identity (e.g., genes (DNA, RNA), DNA and RNA modifications, proteins, protein modifications, lipids, sugars, metals), and abundance (e.g., RNA expression levels, protein translation levels) in a 3D tissue sample.
Resumen de: US20260259203A1
0000 Disclosed is a method that combines high throughput and flexible nature of a cell-free protein microarray with the quantitative capability of surface plasmon resonance to detect>400 different protein interactions in <1 hour. A method of detecting interactions between a targeting agent and one or more proteins of interest is disclosed. The method includes producing a set of proteins of interest using a cell-free protein expression system; providing the set of proteins of interest on a protein microarray wherein each spot in the array comprises a protein of interest; contacting the protein microarray with a targeting agent that binds to one or more of the set of proteins of interest; and detecting the binding of the targeting agent to the set of proteins of interest using surface plasmon resonance imaging (SPRi), thereby detecting the targeting agent and one or more proteins of interest in the micro array.
Resumen de: AU2026216833A1
24521425_1 (GHMatters) P44915AU02 Provided herein are methods for determining the serotype of a virus particle and/or or determining the heterogeneity of a virus particle (e.g., an AAV particle). In other embodiments, the invention provides methods to determine the heterogeneity of AAV particles. In some aspects, the invention provides viral particles (e.g., rAAV particles) with improved stability and/or improved transduction efficiency by increasing the acetylation and/or deamidation of capsid proteins. ug u g
Resumen de: US20260259204A1
Described herein are biosensor microarrays comprising detector polypeptide monolayers substantially free of contaminants. Also provided are methods for generation of such biosensor microarrays by capture of polypeptides by arrays comprising capture moieties and associated sensors.
Resumen de: WO2025090763A1
Methods, kits and compositions of detecting analytes, typically analytes relevant to neurodegenerative diseases such as neurofilament light chain, in a sample are described herein using chemiluminescent labels. Solid supports, reagents, and compounds for use in these methods are also described. Typically, the methods involve specific assay formats which provide the requisite high resolution for detecting low concentrations of analytes in samples and may be used in positions of the healthcare ecosystem close to the patient. These methods, systems, and apparatuses may afford early detection and prognosis of a wide variety of neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis.
Resumen de: CN122162053A
The present application relates to methods for quantifying citrullination and methods that can be used to assess the activity of agents including, for example, PAD4 (peptidyl arginine deiminase 4) modulators, such as small molecules or antibodies. In certain embodiments, the methods comprise assessing citrullination of one or more citrullination sites on a protein or peptide fragment thereof present in a biological sample.
Resumen de: WO2025026904A1
The present invention relates to a microscopy method for obtaining a high-resolution image of a biological sample comprising a substance to be analyzed, wherein an image sequence is obtained by expansion microscopy comprising the steps: g. providing a biological sample, h. mixing said biological sample with a swellable material and forming bonds, preferably covalent bonds, between said substance to be analyzed and the swellable material, thereby forming a mixture, i. fragmenting said substance to be analyzed, j- expanding the mixture comprising said swellable material and said fragmented substance to be analyzed, k. staining the sample either before or after steps (a), (b), (c), or (d) and imaging the obtained mixture under an optical microscope equipped with a camera or a resonant scanner. It also refers to compounds and stabilization chambers for use in such a method.
Resumen de: AU2024293997A1
A machine learning model can be trained to predict brain tau or amyloid β status of a patient using, at least in part, biomarker data of the patient. The brain tau or amyloid β status can include one or more continuous-valued brain tau or amyloid β levels and/or concern brain tau or amyloid β levels in multiple regions of the brain of the patient. A prediction of brain tau or amyloid β status of the patient can be generated by applying the subject data of the patient to the machine learning model. The operations can further include providing the prediction of brain tau or amyloid β status of the patient. The machine learning model be used in selection of patients for treatment with an anti-tau therapy and/or an anti-amyloid therapy, in treatment of patients having or suspected of having Alzheimer's Disease (AD), or in monitoring of AD treatment efficacy.
Resumen de: AU2025215582A1
The present disclosure provides, e.g., signature peptide compounds corresponding to various full-length protein components of the complement enzymatic cascade (e.g., C1q, C1s, C3, C3p, C4, C4p, C5, C5p, FB, and FBp). In one aspect, the invention relates to using these signature peptides for measuring and/or monitoring activation of the complement pathway, e.g., in clinical samples, such as plasma, serum, CSF, aqueous humor, or vitreous humor.
Resumen de: SA520420801B1
Provided a re antigen-binding molecules capable of binding to IL-11, and methods of medical treatment and prophylaxis using the same. Fig 1.
Resumen de: CN122671656A
本发明公开了一种外泌体标志物及其在阿尔茨海默病诊断和治疗中的应用。本发明首次发现，AD患者外周血外泌体中ANXA7蛋白水平显著升高，且其诊断效能良好。本发明还首次揭示，在AD病理条件下，Aβ刺激的小胶质细胞通过外泌体将ANXA7递送至神经元，ANXA7进入神经元后诱导细胞凋亡和氧化应激，从而加速AD进展；使用外泌体抑制剂GW4869或敲低小胶质细胞ANXA7表达可显著减轻神经元损伤。基于上述发现，本发明提供了检测外泌体中ANXA7蛋白水平的试剂在制备AD诊断试剂盒中的应用，以及降低ANXA7表达或活性的物质、抑制外泌体分泌的物质在制备治疗AD的药物中的应用。本发明为AD的早期诊断和靶向治疗提供了新的分子标志物和干预策略。
Resumen de: CN122664983A
本发明涉及生物医药技术领域，具体公开了CLOCK蛋白在调控T‑2毒素致阿尔茨海默症关键因子表达中的应用，其技术要点为：本发明通过T‑2毒素诱导的SH‑SY5Y细胞模型发现：T‑2毒素可诱导721个差异表达基因，显著富集于p53信号通路及昼夜节律通路；T‑2毒素使CLOCK蛋白节律参数发生改变，中值由0.697升至0.861，峰相位由22.34h偏移至7.18h，并诱导p53延迟性持续激活（12h达峰值2.31倍）；CLOCK与p53存在双向调控，形成CLOCK‑p53信号轴；该信号轴通过驱动细胞衰老程序（SA‑β‑gal阳性面积24h达25.13%）介导AD关键因子稳态失衡，表现为APP下降（0.53倍）及p‑Tau（1.19倍）、T‑Tau（1.35倍）升高；CLOCK抑制剂CLK8可减轻Tau异常及衰老表型。本发明为AD防治提供了新靶点。
Resumen de: CN122671666A
0001 本发明涉及一种快速检测微量血液样本中ApoE的微针贴片及其制备方法与应用，属于生物检测技术领域。本发明通过将微针贴片等离子处理后，包被ApoE捕获蛋白，获得快速检测微量血液样本中ApoE的微针贴片。本发明通过等离子体技术对微针表面进行处理，使其获得亲水性，从而可以包被特定蛋白，提高了对捕获蛋白的包被能力，增加了检测的灵敏度和准确性，且制备简单，成本可控。本发明获得的微针贴片用于检测ApoE，不仅具备传统血检的高灵敏度和高准确性，还比传统血检所需血液样本量大大减少，无需静脉抽血，可采用指血检测。相较于现有微针检测技术，本发明为血液样本定量结果，检测结果更可靠。
Resumen de: CN122665107A
本发明属于生物医药领域，具体涉及胰岛素受体INSR‑α作为治疗靶点的应用。本发明提供了特异性结合胰岛素受体INSR‑α的抗体或胰岛素受体INSR‑α信号拮抗剂在制备用于预防和/或治疗肝纤维化的药物中的应用。同时，本发明还提供了一种筛选由MASLD/MASH引起的肝纤维化的药物的方法，所述方法包括，将待测物质给予施用对象；检测施用对象中肝星状细胞的活性；以及判断所述待测物质是否为候选药物的步骤。本发明通过实验证明，通过使用胰岛素受体INSR‑α的中和抗体结合INSR‑α或其信号拮抗剂抑制HSCs的活化，可减轻MASLD/MASH的肝纤维化进程。因此，本发明为由MASLD/MASH引起的肝纤维的治疗提供新途径。
Resumen de: MX2026001711A
The invention provides novel anti-IL-5 proteins, antibodies and IL-5 binding fragments thereof, which inhibit association of IL-5 with IL-5 receptor and are suitable for administration to a human or feline subject. The invention provides novel compositions and methods of treating, alleviating the symptoms of, or preventing, lung diseases, cardiovascular diseases, cancers, metabolic diseases, neurological diseases, and infectious diseases, comprising administering an effective amount of an anti-IL-5 protein, antibody, or fragment thereof. The methods and compositions are used to treat or prevent IL-5-related disorders.
Resumen de: WO2025042785A1
Provided herein are compositions and methods for reducing levels of at least one biomarker in a subject. The at least one biomarker may include p75ECD, PGE-MUM, or both. In some cases, the compositions and methods provided herein involve administering to a subject an amount of a 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitor effective to reduce levels of the at least one biomarker in the subject.
Resumen de: WO2025122947A1
Aspects of the disclosure include methods of monitoring and/or prognosing an adoptive cell therapy in a subject, comprising determining a level of endogenous SCF in a biological sample from the subject, in which the detection of a presence, absence, and/or amount of endogenous SCF is informative of the in vivo activation and/or expansion of the adoptive immune cells, the anti-tumor effect of the adoptive cell therapy, and/or the need for a treatment modification and/or extension. The disclosure also provides a method of treating a disease by administering at least one c-kit agonist (e.g., SCF) simultaneously or sequentially with an adoptive cell therapy.
Resumen de: CN122341632A
The present invention provides material compositions and/or methods useful for the prevention and/or treatment of protein depletion (proteopenia), comprising material compositions that retain the natural function of peptides/proteins while limiting and/or preventing amyloid formation and/or aggregation of the peptides/proteins. Also provided are material compositions and formulations for enhancing peptide/protein solubility, stability, cycle time, receptor interaction, brain permeability, CSF half-life, promoting peptide/protein synthesis and purification.
Resumen de: CN122652033A
本发明公开了一种基于化学发光法检测尿液中β‑淀粉样蛋白前体片段Aβ的试剂组合。它由试剂R1、试剂R2和试剂R3组成；所述试剂R1用磁珠稀释液将偶联β淀粉样蛋白单克隆抗体的羧基磁珠按1:30‑1:60的体积比例稀释而成；所述试剂R2是用吖啶酯稀释液将吖啶酯标记的人源化IgG1单克隆抗体稀释至发光值控制在6000万以上而成；所述试剂R3是用阻断剂稀释液将阻断剂稀释至阻断剂的浓度为8ug/mL以上；所述阻断剂为鼠IgG+HAMA和RF特异性抗体。
Resumen de: WO2025137532A1
Disclosed herein are methods of measuring amyloid β protofibril levels in biological samples. Methods disclosed herein may detect amyloid β protofibril at femtomolar concentrations and selectively measure protofibril as compared to amyloid β monomers.
Resumen de: CN122652060A
本发明公开了一种用于诊断阿尔茨海默病的标志物组合及其应用和试剂盒。本发明的标志物包含外周血中的STMN1蛋白、STMN1mRNA及hsa‑miR‑9‑5p，通过检测外周血样本中STMN1蛋白、STMN1mRNA和靶向STMN1基因的miRNAhsa‑miR‑9‑5p的含量，将数据输入预先经Logistic回归拟合训练得到的诊断模型，即可实现阿尔茨海默病的精准筛查与确诊。相较于脑脊液等侵入式检测方案，本发明采用外周血取样，操作简便、检测成本更低，适合临床大规模无创筛查。
Resumen de: CN122652049A
0001 本发明提供生物标志物在制备用于对2型糖尿病合并代谢综合征患者进行中医证型分型，和/或,用于评估2型糖尿病合并代谢综合征患者认知功能受损风险的产品中的用途，所述生物标志物选自SERPINA3、BACE1或CXCL1中的一种或多种。血清SERPINA3、BACE1、CXCL1水平与中医证型有关联，为中医辨证论治提供实验室依据，有助于提高中医诊断的准确性和规范性，根据血清指标水平和表征，制定个性化的治疗方案；其次，血清指标对认知功能受损有预测价值，有助于早期识别高危患者，延缓认知功能下降。对于病程较长、血糖控制不佳的患者，可定期检测血清指标水平，结合临床指征，及时给予抗炎、营养神经、改善胰岛素抵抗治疗，保护认知功能。
Resumen de: WO2026178362A1
Described herein are polypeptide useful for identifying compound for modulating aberrant protein condensates. The polypeptide comprise a condensate-modulating protein, a first biomarker polypeptide, a barcoding biomarker polypeptide. When inside a cell, the non-natural polypeptide exist as multiple fragments, including a first fragment comprising the condensate-modulating protein and the first biomarker polypeptide, and a second fragment comprising the barcoding biomarker polypeptide. The barcoding biomarker polypeptide is uniquely associated with and identifies the cell expressing associated condensate-modulating protein. Also described is a polynucleotide encoding the non-natural polypeptide, a library of the polynucleotide, and a method of identifying compound for modulating aberrant protein condensates using the non-natural polypeptide, the construct, and/or the library.
Resumen de: WO2026178077A1
The present disclosure relates to methods and compositions for editing an AMPK polynucleotide encoding an AMPK protein. The disclosure also relates to methods and compositions for modulating activity of an AMPK protein, for promoting activation of an AMPK protein, for repairing function of a pathogenic AMPK protein, and methods for regulating energy homeostasis and/or for treating or preventing an AMPK-associated disease or condition in a subject.
Nº publicación: AU2025374616A1 27/08/2026
Solicitante:
SIEMENS HEALTHCARE DIAGNOSTICS INC
SIEMENS HEALTHCARE DIAGNOSTICS INC.
Resumen de: AU2025374616A1
Methods of detecting analytes in a sample are described herein using chemiluminescent labels and branched DNA. Solid supports, reagents, and compounds for use in these methods are also described. Typically, the methods involve specific assay formats which provide the requisite high resolution for detecting low concentrations of analytes such as exosome protein biomarkers in samples.
BOPI
Sede Electrónica
